

REMARKS

Claims 3 and 5-25 have been cancelled without prejudice. Claims 1, 2, and 4 have been amended. New claims 26-34 have been added. Accordingly, claims 1, 2, 4, and 26-34 are currently pending. *No new matter has been added.*

Support for the amendments to the claims and the new claims can be found in the specification and claims as originally filed.

Any amendment to or cancellation of the claims is not to be construed as an acquiescence to any of the rejections set forth in the instant Office Action, and was done solely to expedite prosecution of the application. Applicants reserve the right to pursue the subject matter of the claims as originally filed in this or a separate application(s).

Applicants submit herewith a "**Version with Markings to Show Changes Made,**" which indicates the specific amendments made the specification.

SEARCHED - INDEXED - SERIALIZED - FILED

CONCLUSION

It is respectfully requested that the above amendment be entered. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at the number provided below.

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By _____
Amy E. Mandragouras, Esq.
Reg. No. 36,207
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400
(617) 742-4214
Date: July 12, 2001

PCT/US2001/024260

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 1 has been amended as follows:

1. (Amended) A method of inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a P-selectin glycoprotein ligand (PSGL) antagonist.

Claim 2 has been amended as follows:

2. (Amended) The method of claim 1, wherein said P-selectin glycoprotein ligand (PSGL) antagonist is selected from the group consisting of a soluble form of PSGL, an antibody directed to PSGL, an antibody directed to sLe_x, an antibody directed to sulfated tyrosine, sLe_x, mimetics which inhibit sLe_x binding and a small molecule inhibitor of PSGL binding.

Claim 4 has been amended as follows:

4. (Amended) The method of claim 2, wherein said PSGL antagonist is an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.

Claim 26 has been added as follows:

26. (New) The method of claim 4, wherein said antibody is a monoclonal antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.

Claim 27 has been amended as follows:

27. (New) The method of claim 4, wherein said antibody is administered in a pharmaceutically acceptable formulation.

Claim 28 has been amended as follows:

28. (New) A method for treating or ameliorating, in a subject, a disease or condition resulting from differentiation of activated T-cells into cytotoxic lymphocytes comprising administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.

Claim 29 has been amended as follows:

29. (New) The method of claim 28, wherein said disease or condition is an autoimmune condition.

Claim 30 has been amended as follows:

30. (New) The method of claim 28, wherein said disease or condition is an allergic reaction.

Claim 31 has been amended as follows:

31. (New) The method of claim 28, wherein said disease or condition is asthma.

Claim 32 has been amended as follows:

32. (New) The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof.

Claim 33 has been amended as follows:

33. (New) The method of claim 28, wherein said subject is a mammalian subject.

Claim 34 has been amended as follows:

34. (New) The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.

PCT/US2007/008450